The patent highlights the versatility of the nucleic acid molecule, which can be delivered via viral vectors, such as lentiviral vectors, thereby expanding its potential applications in therapeutic ...

Following a comprehensive review of its operations, bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company’s cost structure ...

Oxford Biomedica, a prominent gene and cell therapy company, reported significant revenue growth alongside strategic ...

Oxford Biomedica, which recently rebranded to OXB, told investors that it expected continued growth in the second half of the ...

Oxford Biomedica plc ( OTCPK:OXBDF) Q2 2024 Earnings Conference Call September 23, 2024 8:00 AM ET Frank Mathias - Chief Executive Officer Sebastien Ribault - Chief Business Officer Lucinda Crabtree - ...

A new bioprocessing technique developed by a team of researchers could improve a range of therapies based on CAR-T cells.

Co-expressing NPY and its inhibitory receptor Y2 in excitatory hippocampal cells allows inhibitory autoregulation of ...

Recent findings reveal that induced satellite cells can effectively regenerate muscle tissue, outperforming traditional ...

Researchers tested a preclinical model for an experimental gene therapy designed to treat multiple sulfatase deficiency (MSD), a disorder that affects the brain, lungs, skin, and skeleton with no ...